Breakthrough In Experimental HIV Vaccine Prevents Infections In 31% Of Cases

A phase III efficacy trial organized by the U.S. Military HIV Research Program and the Thai Ministry of Public Health, involving 16,000 volunteers in Thailand has revealed that volunteers who received a prime-boost combination of two AIDS vaccine candidates - ALVAC combined with AIDSVAX - had infection rates 31.2% lower than people who received a placebo.